$GRPOF Tetra Bio-Pharma files patent for treatment of cancer, ocular disease
Tetra Bio-Pharma Inc. (CSE: C.TBP, OTCQB: GRPOF, Forum) said Thursday it has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.
The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics.
The Ontario-based company was in the news recently when it and and Aphria Inc. (TSX: V.APH, OTCQB: APHQF, Forum) announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.